HIV and Peripheral Artery Disease: Acknowledging the Association

The role of human immunodeficiency virus (HIV) in the development of vascular disease (specifically peripheral artery disease) remains unclear. Is the virus per se the direct cause of this disease or is it a consequence of dyslipidemia, one of the adverse effects of antiretrovirals?

This study looked into the effect of HIV infection on peripheral artery disease after adjusting for all traditional risk factors in a large cohort of HIV+ patients and compared them with an uninfected population of similar baseline characteristics.

 

Of 91953 participant patients with a mean follow up of 9 years, researchers observed 7708 peripheral vascular events. Events rate per 1000 patient/year was higher among HIV+ patients (11.9% vs 9.9%).


Read also: MITRA-FR: Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation.


After adjusting for multiple demographic factors, traditional cardiovascular risk factors and other covariates, it was observed that HIV+ patients have higher incidence of peripheral vascular events, and the difference turned out to be significant (HR 1.19, CI 95%, 1.13 to 1.25).

 

Events risk was 1.5 fold higher in patients with viral load >500 copies/ml and nearly 2 fold higher in those with CD4 cell counts <200 cells/mm3, even though this had no effect in amputations rate. On the contrary, HIV+ patients with undetectable viral load and with CD4 cell counts ≥500/mm³ had identical events rate as uninfected patients.


Read also: OCT Provides Hints About the Physiopathology Behind Very Late Stent Thrombosis.


Mortality after vascular event was higher regardless HIV infection.

 

Conclusion

HIV infection was associated with a 19% increased risk of peripheral artery disease, beyond that explained by traditional risk factors. For patients with CD4 cell counts <200/mm³, risk resulted nearly 2-fold higher, whilst patients under control had similar risk as HIV negatives.

 

Original title: Association of Human Immunodeficiency Virus Infection and Risk of Peripheral Artery Disease.

Reference: Joshua A. Beckman et al. Circulation. 2018;138:255–265.

 

2018-09-10 HIV-y-vascular-periferica.full


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE

Pulmonary embolism (PE) continues to be the third cause of cardiovascular mortality. The current clinical guidelines recommend anticoagulation in intermediate risk patients presenting right...

Atherosclerotic Renal Artery Stenosis: To Revascularize or Not

At long term, atherosclerotic renal artery stenosis (RAS) can lead to hypertension, chronic kidney disease, and cardiac failure. Historically, these patients have been referred...

Endovascular Management of Chronic TEPH: Is Coronary Management Extrapolatable in This Scenario?

Chronic thromboembolic pulmonary hypertension (CTEPH) is a condition that causes significant functional limitation. Its surgical treatment, known as pulmonary endarterectomy (PEA), has improved the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...